# Rituximab in Treating Patients With Multiple Myeloma

> **NCT00003554** · PHASE2 · COMPLETED · sponsor: **The Cleveland Clinic**

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **BIOLOGICAL:** rituximab
- **DRUG:** melphalan
- **DRUG:** prednisone

## Key facts

- **NCT ID:** NCT00003554
- **Lead sponsor:** The Cleveland Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-11
- **Primary completion:** —
- **Final completion:** 2004-04
- **Target enrollment:** — (—)
- **Last updated:** 2013-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003554, "Rituximab in Treating Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00003554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*